Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

elagolix MeSH Supplementary Concept Data 2025


MeSH Supplementary
elagolix
Unique ID
C539351
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/C539351
Entry Term(s)
Orilissa
R-(+)-4-(2-(5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-(trifluoromethyl)benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl)-1-phenylethylamino)butyrate
elagolix sodium
Registry Numbers
5B2546MB5Z
Heading Mapped to
*Hydrocarbons, Fluorinated
*Pyrimidines
Frequency
73
Note
an orally available nonpeptide GnRH antagonist
Source
J Clin Endocrinol Metab 2009 Feb;94(2):545-51
Date of Entry
2009/03/26
Revision Date
2020/02/28
elagolix Preferred
R-(+)-4-(2-(5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-(trifluoromethyl)benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl)-1-phenylethylamino)butyrate Related
Orilissa Related
elagolix sodium Related
page delivered in 0.006s